Abstract
Purpose :
To compare clinical outcomes between four different methods of transscleral cyclophotocoagulation (TSCPC).
Methods :
Retrospective study of 194 patients (1684 visits) who underwent MicroPulse cyclophotocoagulation using the generation two MicroPulse probe with traditional settings (MPCPC n=50), augmented settings (augMPCPC n=50), Augmented MPCPC with limited continuous-wave CPC (augMPCPC with limCWCPC n=47) or continuous-wave CPC alone (CWCPC n=47). Kaplan-Meier (KM) curves assessed survival (1) without meds [CS – complete success] or (2) with ≤ baseline meds [QS – qualified success], while maintaining IOP reduction ≥ 20% with 5 mmHg ≤ IOP ≤ 21 mmHg for at least two consecutive visits.
Results :
Baseline demographics were similar amongst the groups except for IOP (P<0.01) and meds (P<0.01). Both of these values were controlled by a Cox Proportional Hazard ratio model. Under CS criteria, the success rate was not significantly different between groups up to POY1 and was uniformly low ranging between 3-8% (P=0.25). Under the QS criteria, success rates were significantly higher for augMPCPC with limCWCPC (74%) and augMPCPC (70%) at POM6 (vs 34% for MPCPC and 28% CWCPC, P<0.01). They were also significantly higher for augMPCPC (66%) and augMPCPC with limCWCPC (63%) at POY1 (vs 28% for CWCPC and 20% for MPCPC, P<0.01).
Conclusions :
When less than or equal medications to baseline are allowed, augMPCPC with limCWCPC and augMPCPC with the generation two MicroPulse probe appear to confer longer KM survival than CWCPC and traditional MPCPC. While all methods of TSCPC were efficacious at maintaining ≥ 20% IOP reduction from baseline, most patients still required IOP-lowering medications.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.